Quick Answer
ImmunityBio, Inc. reported Research And Development Expense of $190.14 million for the year ending 2024.
- ImmunityBio, Inc. showed a decrease of -18.2% in Research And Development Expense from 2023 to 2024.
- This data is from ImmunityBio, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2013 to 2024), ImmunityBio, Inc.'s Research And Development Expense has grown by 42,533.2%.
- Historical annual values: Fiscal year 2024: $190.14 million | Fiscal year 2023: $232.37 million | Fiscal year 2022: $248.15 million | Fiscal year 2021: $195.96 million | Fiscal year 2020: $139.51 million | Fiscal year 2019: $112.00 million | Fiscal year 2018: $55.72 million | Fiscal year 2017: $42.04 million | Fiscal year 2016: $29.15 million | Fiscal year 2015: $11.43 million | Fiscal year 2014: $1.60 million | Fiscal year 2013: $446.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: